Positron Corporation Sees Expanded Market Opportunity for Attrius PET Scanner with FDA Approval of Eli Lilly's Amyvid

Strategic Insights -

Positron Corporation, a molecular imaging solutions company focused on nuclear cardiology, is poised to tap into a larger market with the conditional approval of Eli Lilly's PET imaging agent Amyvid for detecting beta-amyloid plaque deposits associated with Alzheimer's disease. The approval, which was conditionally recommended by an FDA advisory committee on January 20th, creates a substantial opportunity for Positron's Attrius PET scanner to expand its product offerings into the neurologic market segment. With an estimated five million Americans affected by Alzheimer's disease, the demand for accurate detection and diagnosis is high, and Positron's Attrius PET system is well-positioned to meet this need.

Key Takeaways:

  • Positron Corporation expects to see an expanded market opportunity for its Attrius PET scanner with the conditional FDA approval of Eli Lilly's PET imaging agent Amyvid.
  • The approval of Amyvid creates a clinical need to identify Alzheimer's disease patients with beta-amyloid, paving the way for Positron's Attrius PET scanner to tap into this growing market.
  • Positron's Attrius PET system is an ideal choice for brain imaging due to its small footprint and cost-effective pricing, making it a competitive option for neurologic applications.
  • The current estimate of five million Americans affected by Alzheimer's disease highlights the significant market opportunity for companies like Positron to provide accurate detection and diagnosis solutions.
  • Eli Lilly's product, Amyvid, has the ability to detect amyloid plaque, and the future commercial availability of an anti-amyloid therapeutic agent will further drive the demand for detection and diagnosis tools.
  • Patrick G. Rooney, CEO of Positron, stated that the company will continue to identify additional applications for its Attrius PET scanner, expanding its product offerings beyond current market segments.

Statistics:

  • Approximately five million Americans are affected by Alzheimer's disease (source: Alzheimer's Association).
  • The FDA advisory committee conditionally recommended approval of Eli Lilly's PET imaging agent Amyvid on January 20th.
  • Positron's Attrius PET system offers cost-effective pricing without the need for traditional CT imaging, making it an attractive option for neurologic applications.
  • The market opportunity for Positron's Attrius PET scanner is substantial, with the growing need for accurate detection and diagnosis of Alzheimer's disease and other neurologic conditions.

Sources:

  • Positron Corporation, News Release, January 20th
  • Alzheimer's Association, "Alzheimer's Disease Facts and Figures"
  • Eli Lilly and Company, "Amyvid (florbetapir F 18) PET Imaging Agent for the Detection of Beta-amyloid Plaques in the Brain"